small cell carcinoma

Summary

Summary: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. There are admixtures of small cell lung carcinoma with other types of lung cancer. Small cell carcinomas are distinguished by their distinctive biological features, response to chemotherapy and radiotherapy, and by their nearly universal tendency to develop overt or subclinical metastases, which frequently eliminates surgery in most patients. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)

Top Publications

  1. ncbi Management of primary small cell carcinoma of the esophagus
    Ke lin Sun
    Department of Thoracic Surgery, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Chin Med J (Engl) 120:355-8. 2007
  2. ncbi Small-cell lung cancer
    David M Jackman
    Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 366:1385-96. 2005
  3. ncbi Small cell carcinoma with concomitant adenocarcinoma arising in a Barrett's oesophagus: report of a case with a favourable behaviour
    Frederic Bibeau
    Department of Pathology, Centre Regional de Lutte contre le Cancer Val d Aurelle, 208 Rue des Apothicaires, Montpellier Cedex 5, France
    Virchows Arch 452:103-7. 2008
  4. ncbi Clinicopathologic features and histochemical analyses of proliferative activity and angiogenesis in small cell carcinoma of the esophagus
    Naohiko Koide
    Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan
    J Gastroenterol 42:932-8. 2007
  5. pmc Primary small cell carcinoma of the breast with TTF-1 and neuroendocrine marker expressing carcinoma in situ
    Michael Christie
    Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville, Victoria, Australia
    Int J Clin Exp Pathol 3:629-33. 2010
  6. ncbi Small cell lung cancer
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Suite 3170, Tampa, FL 33612, USA
    Chest 123:259S-271S. 2003
  7. ncbi Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer
    Charles M Rudin
    University of Chicago, Illinois, USA
    J Clin Oncol 22:1110-7. 2004
  8. ncbi Small cell carcinoma of the female genital tract
    Sara Crowder
    Mid Missouri Gynecologic Oncology, Columbia, MO 65201, USA
    Semin Oncol 34:57-63. 2007
  9. ncbi Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis
    E Steels
    , Institut Jules Bordet, , Brussels, Belgium
    Eur Respir J 18:705-19. 2001
  10. ncbi c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions
    Patrick C Ma
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 63:6272-81. 2003

Detail Information

Publications380 found, 100 shown here

  1. ncbi Management of primary small cell carcinoma of the esophagus
    Ke lin Sun
    Department of Thoracic Surgery, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Chin Med J (Engl) 120:355-8. 2007
    Primary small cell carcinoma of the esophagus is rare...
  2. ncbi Small-cell lung cancer
    David M Jackman
    Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 366:1385-96. 2005
    ..For patients who survive long term, careful monitoring for development of a second primary tumour is necessary, with further investigation and treatment as appropriate...
  3. ncbi Small cell carcinoma with concomitant adenocarcinoma arising in a Barrett's oesophagus: report of a case with a favourable behaviour
    Frederic Bibeau
    Department of Pathology, Centre Regional de Lutte contre le Cancer Val d Aurelle, 208 Rue des Apothicaires, Montpellier Cedex 5, France
    Virchows Arch 452:103-7. 2008
    ..Moreover, it is particular because of its favourable behaviour, with a 6-year disease-free survival, after neoadjuvant chemoradiation, surgery and postoperative chemotherapy...
  4. ncbi Clinicopathologic features and histochemical analyses of proliferative activity and angiogenesis in small cell carcinoma of the esophagus
    Naohiko Koide
    Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan
    J Gastroenterol 42:932-8. 2007
    We investigated clinicopathologic features in patients with esophageal small cell carcinoma (SCEC), and its proliferative activity and angiogenesis.
  5. pmc Primary small cell carcinoma of the breast with TTF-1 and neuroendocrine marker expressing carcinoma in situ
    Michael Christie
    Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville, Victoria, Australia
    Int J Clin Exp Pathol 3:629-33. 2010
    Primary small cell carcinoma (SmCC) of the breast is very rare and may be difficult to distinguish from metastatic small cell carcinoma...
  6. ncbi Small cell lung cancer
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Suite 3170, Tampa, FL 33612, USA
    Chest 123:259S-271S. 2003
    ..Relapsed or refractory SCLC has a uniformly poor prognosis. In this section, evidence-based guidelines for the staging and treatment of SCLC are outlined...
  7. ncbi Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer
    Charles M Rudin
    University of Chicago, Illinois, USA
    J Clin Oncol 22:1110-7. 2004
    ..A dose-finding study was performed evaluating the combination of G3139, carboplatin, and etoposide in patients with previously untreated extensive stage SCLC...
  8. ncbi Small cell carcinoma of the female genital tract
    Sara Crowder
    Mid Missouri Gynecologic Oncology, Columbia, MO 65201, USA
    Semin Oncol 34:57-63. 2007
    b>Small cell carcinoma (SCC) of the female genital tract is rare, constituting less than 2% of all gynecologic malignancies...
  9. ncbi Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis
    E Steels
    , Institut Jules Bordet, , Brussels, Belgium
    Eur Respir J 18:705-19. 2001
    ..Data were insufficient to determine the prognostic value of p53 in small cell lung cancer. In each subgroup of nonsmall cell lung cancer, p53 abnormal status was shown to be associated with a poorer survival prognosis...
  10. ncbi c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions
    Patrick C Ma
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 63:6272-81. 2003
    ..It would now be useful to study the inhibition of c-MET as a therapeutic target against SCLC...
  11. ncbi Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma
    Pingfang Song
    Department of Pathology, Oregon Health and Science University, Portland, Oregon 97239, USA
    Cancer Res 63:214-21. 2003
    ..These findings demonstrate that SCLC can synthesize, secrete, and degrade ACh and that released ACh stimulates SCLC cell growth. Identification of this new autocrine loop provides a potential new target for therapeutic intervention...
  12. ncbi Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database
    Ramaswamy Govindan
    Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Oncol 24:4539-44. 2006
    ..Small-cell lung cancer (SCLC) is a histologic subtype of lung cancer with a distinct biology and clinical course. It has been observed that the incidence of SCLC has been decreasing over the last several years...
  13. ncbi Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel
    Jun ichi Nitadori
    Pathology Division, National Cancer Center Research Institute East, 6 5 1 Kashiwanoha, Kashiwa shi, Chiba 277 8577, Japan
    Am J Clin Pathol 125:682-92. 2006
    ....
  14. ncbi Gamma knife radiosurgery for metastatic brain tumors from lung cancer: a comparison between small cell and non-small cell carcinoma
    Toru Serizawa
    Department of Neurosurgery, Chiba Cardiovascular Center, Ichihara, Japan
    J Neurosurg 97:484-8. 2002
    ....
  15. ncbi Small-cell lung cancer (human): potentiation of endocytic membrane activity by voltage-gated Na(+) channel expression in vitro
    P U Onganer
    Neuroscience Solutions to Cancer Research Group, Department of Biological Sciences, Sir Alexander Fleming Building, Imperial College London, South Kensington Campus, London SW7 2AZ, UK
    J Membr Biol 204:67-75. 2005
    ..Both drugs inhibited HRP uptake, thereby suggesting that basal cholinergic activity occurred. It is concluded that VGSC upregulation could enhance metastatic cell behavior in SCLC by enhancing endocytic membrane activity...
  16. ncbi Esophageal small cell carcinomas: clinicopathologic parameters, p53 overexpression, proliferation marker, and their impact on pathogenesis
    K Y Lam
    Department of Pathology, University of Hong Kong, Hong Kong
    Arch Pathol Lab Med 124:228-33. 2000
    To evaluate the clinicopathologic features and the roles of p53 and MIB-1 in esophageal small cell carcinoma.
  17. ncbi Small cell carcinoma of the esophagus: the Tata Memorial Hospital experience
    Gouri H Pantvaidya
    Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India
    Ann Thorac Surg 74:1924-7. 2002
    b>Small cell carcinoma of the esophagus is a rare disease, characterized by aggressive progression. It has a high incidence of metastatic disease at presentation and a poor overall prognosis...
  18. pmc Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
    A Bhattacharjee
    Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 98:13790-5. 2001
    ..These results suggest that integration of expression profile data with clinical parameters could aid in diagnosis of lung cancer patients...
  19. doi Primary small cell carcinoma of the esophagus
    Jima Lv
    Department of Radiation Oncology, Cancer Hospital Institute, Peking Union Medical College, Chinese Academy of Medical Sciences, China
    J Thorac Oncol 3:1460-5. 2008
    ..Primary small cell esophageal carcinoma (SCEC) is a rare and aggressive disease for which there is no recommended standard treatment at this time...
  20. ncbi Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis
    S A Khuder
    Medical College of Ohio, 3120 Glendale Ave, Toledo, OH 43614 5809, USA
    Lung Cancer 31:139-48. 2001
    ..The association was stronger with squamous cell carcinoma (SQC) and small cell carcinoma (SCLC) than with large cell cancer (LGC) and adenocarcinoma (ADC)...
  21. ncbi Chromosomal imbalances in human lung cancer
    Binaifer R Balsara
    Human Genetics Program, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, Pennsylvania 19111, USA
    Oncogene 21:6877-83. 2002
    ..The molecular implications of consistent chromosome imbalances found in lung cancer to date are also discussed...
  22. doi Surgical management for small cell carcinoma of the esophagus
    T Tanaka
    Department of Surgery, Kurume University School of Medicine, Fukuoka, Japan
    Dis Esophagus 23:502-5. 2010
    Esophageal small cell carcinoma (SmCC) has been regarded as a rare and aggressive tumor with early metastasis. The optimal treatment has not yet been established, and the role of surgery has remained controversial...
  23. ncbi Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer
    Ajit Bharti
    Department of Medicine, Center for Molecular Stress Response, Boston University School of Medicine, 88 East Newton Street, Boston, MA 02118, USA
    Anticancer Res 24:1031-8. 2004
    ..Small cell lung cancer (SCLC) frequently presents as metastatic disease. It would be useful to detect serum tumor biomarkers at an earlier stage in order to improve the overall survival...
  24. ncbi Immunohistochemical distinction between merkel cell carcinoma and small cell carcinoma of the lung
    Mattheos Bobos
    Department of Pathology, Aristotle University Medical School, Thessaloniki, Greece
    Am J Dermatopathol 28:99-104. 2006
    ..These findings suggest that a set of three immunohistochemical stains, including CK20, NF, and TTF-1, is useful in affording a distinction between Merkel cell carcinoma and small cell lung carcinoma...
  25. pmc Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994
    M P Lebitasy
    Service de Pneumologie Lyautey, CHU de Strasbourg, 1 rue des Canonniers, 67100 Strasbourg, France
    Br J Cancer 85:808-15. 2001
    ..Survival time has truly improved as 'state of the art' management of SCLC has changed...
  26. ncbi Successful treatment of neuroendocrine small cell carcinoma of the cervix metastatic to regional lymph nodes
    Y B Kim
    Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California, USA
    Gynecol Oncol 62:411-4. 1996
    Neuroendocrine small cell carcinoma of the cervix is an aggressive tumor that is associated with a poor prognosis. No reports have described a patient with metastatic spread who has had long-term survival...
  27. ncbi High expression of integrin beta1 and p53 is a greater poor prognostic factor than clinical stage in small-cell lung cancer
    Fumihiro Oshita
    Department of Thoracic Oncology, Kanagawa Cancer Center, Nakao, Asahi ku, Yokohama, Japan
    Am J Clin Oncol 27:215-9. 2004
    ..394, p = 0.0005). In conclusion, the high expression of integrin beta1 and p53 in tumor cells is a greater poor prognostic factor than clinical stage in patients with SCLC...
  28. ncbi Gain of a region on 7p22.3, containing MAD1L1, is the most frequent event in small-cell lung cancer cell lines
    Bradley P Coe
    British Columbia Cancer Research Centre, Vancouver, BC, Canada
    Genes Chromosomes Cancer 45:11-9. 2006
    ..Intriguingly, MAD1L1 has been implicated to have tumor-suppressing functions. Our data suggest a more complex role for this gene, as MAD1L1 is the most frequent copy number gain in SCLC cell lines...
  29. ncbi Small cell carcinoma of the gallbladder: a clinicopathologic, immunohistochemical, and molecular pathology study of 12 cases
    A Maitra
    Departments of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Am J Surg Pathol 25:595-601. 2001
    ..In contrast to pulmonary small cell carcinomas, p16INK4a function appears to be abrogated more frequently in these carcinomas...
  30. ncbi Long-term survivors after the resection of limited esophageal small cell carcinoma
    M Mitani
    Department of Surgery II, Nagoya City University School of Medicine, Nagoya, Japan
    Dis Esophagus 13:259-61. 2000
    Patients with small cell carcinoma of the esophagus have a poor prognosis and have generally been treated by chemotherapy. However, all reported cases were at advanced stages...
  31. pmc Outcome of recurrent and metastatic small cell carcinoma of the bladder
    Nabil Ismaili
    Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco
    BMC Urol 9:4. 2009
    Bladder small cell carcinoma is an uncommon tumour. Through a retrospective study we will present the evolution of recurrent and metastatic disease and outcome of patients treated at Léon-Bérard Cancer Centre.
  32. doi Incidence, mortality, and prognostic factors of small cell carcinoma of the cervix
    Jergin Chen
    Department of Radiation Oncology, Huntsman Cancer Institute, Salt Lake City, Utah 84112, USA
    Obstet Gynecol 111:1394-402. 2008
    To compare the incidence, mortality, and presentation of small cell carcinoma of the cervix with other histologies.
  33. ncbi A case of primary small cell carcinoma of the breast
    Hidekazu Kitakata
    Division of Surgical Oncology, Cancer Research Institute, Kanazawa University, Japan
    Breast Cancer 14:414-9. 2007
    We report a rare case of primary small cell carcinoma of the breast. A 44-year-old woman was admitted to our hospital with a mass in her left breast...
  34. ncbi International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising
    Susan S Devesa
    Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Cancer 117:294-9. 2005
    ..Most lung cancers are squamous cell carcinoma, small cell carcinoma, or adenocarcinoma; trends vary according to type...
  35. ncbi Treatment outcomes of small cell carcinoma of the prostate: a single-center study
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1729-37. 2007
    The current study was conducted to determine the clinical characteristics and prognostic features associated with prostatic small cell carcinoma (SCC).
  36. ncbi The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth
    G W Krystal
    Department of Medicine, Virginia Commonwealth University, McGuire Veterans Affairs Medical Center, Richmond 23249, USA
    Clin Cancer Res 6:3319-26. 2000
    ....
  37. doi Clinical and therapeutic aspects of extrapulmonary small cell carcinoma
    Annemiek M E Walenkamp
    Department of Medical Oncology, University Medical Centre Groningen and University of Groningen, P O Box 30001, 9700 RB Groningen, The Netherlands
    Cancer Treat Rev 35:228-36. 2009
    Extrapulmonary small cell carcinoma (EPSCC) is usually treated similarly to small cell lung cancer...
  38. ncbi Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants
    W L Gerald
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 16:3028-36. 1998
    ..We reviewed 109 cases of DSRCT to further characterize this entity better...
  39. ncbi Small cell lung cancer: state of the art and future perspectives
    Roger Stupp
    Multidisciplinary Oncology Center, University Hospital CHUV, 46, Rue du Bugnon, 1011 Lausanne, Switzerland
    Lung Cancer 45:105-17. 2004
    ..Particular emphasis is given to the importance of concomitant and accelerated radiotherapy and consideration of dose-intensive combination chemotherapy regimens...
  40. ncbi Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases
    Wenle Wang
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Am J Surg Pathol 32:65-71. 2008
    b>Small cell carcinoma of prostate is rare, with the literature consisting of case reports and small series...
  41. ncbi Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer
    H Schirrmeister
    Department of Nuclear Medicine, University of Ulm, Ulm, Germany
    J Nucl Med 42:1800-4. 2001
    ..Routinely performed SPECT imaging is practicable, is cost-effective, and improves the accuracy of BS...
  42. ncbi Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
    Kazumasa Noda
    Kanagawa Cancer Center, Yokohama, Japan
    N Engl J Med 346:85-91. 2002
    ..In a phase 2 study of irinotecan plus cisplatin in patients with extensive small-cell lung cancer, there was a high response rate and a promising median survival time...
  43. ncbi Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients
    Liang Cheng
    Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis 46202, USA
    Cancer 101:957-62. 2004
    b>Small cell carcinoma of the urinary bladder is an uncommon tumor that has been described in case reports or small series. Herein, the authors report a series of 64 patients with small cell carcinoma of the urinary bladder.
  44. ncbi Small cell carcinoma of the urinary bladder. The Mayo Clinic experience
    Nicholas W W Choong
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 103:1172-8. 2005
    b>Small cell carcinoma (SCC) of the urinary bladder accounts for 0.35-0.70% of all bladder tumors. There is no standard approach to the management of SCC of the urinary bladder.
  45. ncbi Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up
    Stein Sundstrøm
    Department of Oncology, University Hospital of Trondheim
    J Clin Oncol 20:4665-72. 2002
    ..To investigate whether chemotherapy with etoposide and cisplatin (EP) is superior to cyclophosphamide, epirubicin, and vincristine (CEV) in small-cell lung cancer (SCLC)...
  46. ncbi Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer
    D Neil Watkins
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Nature 422:313-7. 2003
    ..This requirement for Hh pathway activation identifies a common lethal malignancy that may respond to pharmacological blockade of the Hh signalling pathway...
  47. ncbi Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104
    Minoru Takada
    Osaka Prefectural Habikino Hospital, Osaka City General Medical Center, Kinki National Hospital for Chest Disease, Osaka, Japan
    J Clin Oncol 20:3054-60. 2002
    ....
  48. doi Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients
    Joshua G Cohen
    Division of Gynecologic Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA
    Am J Obstet Gynecol 203:347.e1-6. 2010
    ..To determine the clinicopathologic factors associated with survival in neuroendocrine small cell cervical cancer patients...
  49. ncbi Results of surgery in small cell carcinoma of the lung
    David Gomez de Antonio
    Hospital Universitario Puerta de Hierro, c San Martin de Porres, 4 28035, Madrid, Spain
    Lung Cancer 52:299-304. 2006
    ..Our study reports the survival rate of 47 patients with small cell lung cancer treated surgically...
  50. doi Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts
    Lilach Agemy
    Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
    Prostate 68:530-9. 2008
    b>Small cell carcinoma of the prostate (SCCP) is a rare subset of prostate cancer (0.5-2% of all prostatic carcinomas), predominantly composed of neuroendocrine (NE) cells, with a very poor prognosis...
  51. ncbi Small cell carcinoma of the head and neck: a review
    Gregory Renner
    Department of Otolaryngology Head and Neck Surgery, University of Missouri School of Medicine, Columbia, MO 65212, USA
    Semin Oncol 34:3-14. 2007
    b>Small cell carcinoma (SCC) has become recognized as a distinct, though relatively infrequent, clinical pathology that occurs in multiple sites throughout the head and neck...
  52. doi Thyroid transcription factor-1 and "basal marker"--expressing small cell carcinoma of the breast
    Cagatay Ersahin
    Department of Pathology, Loyola University Medical Center, Maywood, Illinois, USA
    Int J Surg Pathol 17:368-72. 2009
    b>Small cell carcinoma of the breast is a very rare entity that is histologically indistinguishable from small cell carcinomas of other organs...
  53. ncbi Poorly differentiated small cell carcinoma of the pancreas. A case report and review of the literature
    Simone Berkel
    Department of Medicine II, Mannheim Medical Faculty, University of Heidelberg, Heidelberg, Germany
    Pancreatology 4:521-6. 2004
    b>Small cell carcinoma (SCC) of the pancreas is a rare malignancy with an extremely poor prognosis...
  54. pmc A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer
    E F Smit
    Department of Pulmonary Diseases, University Hospital Groningen, The Netherlands
    Br J Cancer 77:347-51. 1998
    ..Paclitaxel is active in drug-resistant SCLC. Further investigation in combination with other active agents in this poor prognosis group is appropriate...
  55. ncbi Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy
    P J Hoskins
    British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, BC, Canada, V5Z 4E6
    J Clin Oncol 21:3495-501. 2003
    ..To determine the efficacy and toxicity of a combined-modality regimen of irradiation with platinum-based combination chemotherapy in small-cell carcinoma of the cervix (SCCC)...
  56. ncbi An immunohistochemical analysis of ovarian small cell carcinoma of hypercalcemic type
    W G McCluggage
    Department of Pathology, Royal Group of Hospitals Trust, Belfast, Northern Ireland
    Int J Gynecol Pathol 23:330-6. 2004
    Ovarian small cell carcinoma of hypercalcemic type (OSCCHT) is a rare neoplasm with an aggressive behavior, broad differential diagnosis, and unknown histogenesis...
  57. ncbi Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmona
    Andrea Ardizzoni
    Medical Oncology, Parma University Hospital, Via Gramsci 14, 43100 Parma, Italy
    J Clin Oncol 23:569-75. 2005
    ..We conducted a randomized two-stage phase II study to assess the therapeutic index of two different platinum/etoposide regimens, attenuated-dose (AD) and full-dose (FD) plus prophylactic lenograstim...
  58. ncbi Small cell carcinoma of the esophagus; clinicopathological and immunohistochemical analysis of six cases
    T Noguchi
    Department of Oncological Science Surgery II, Oita Medical University, Oita, Japan
    Dis Esophagus 16:252-8. 2003
    b>Small cell carcinoma arising in the esophagus is a relatively rare disease. In the more common small cell carcinoma of the lung, the diagnostic significance of several new markers has been recently reported...
  59. ncbi Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach
    Hong Zhang
    Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston Medical School, Houston, TX 77030, USA
    Mod Pathol 18:111-8. 2005
    Accurate morphologic distinction between small cell carcinoma and poorly differentiated squamous cell carcinoma has critical therapeutic significance, but can be limited by crush artifact, tumor necrosis, limited tumor representation, and ..
  60. ncbi Extrapulmonary small cell carcinoma--a medical center's experience
    Tai Lin Huang
    Division of Hematology Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan, R O C
    Chang Gung Med J 29:590-5. 2006
    To review the biologic behavior, therapy and natural courses of patients with extrapulmonary small cell carcinoma (EPSCC) in a medical center.
  61. ncbi Synchronus presentation of early-stage small cell carcinoma and adenocarcinoma in the same lung lobe
    Yoshihiro Kobashi
    Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, Matsushima, Kurashiki
    Intern Med 45:287-91. 2006
    ..A histological diagnosis (small cell carcinoma) was obtained by bronchoscopic examination including a transbronchial lung biopsy (TBLB)...
  62. ncbi Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study
    David S Ettinger
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    J Clin Oncol 23:4991-8. 2005
    ....
  63. ncbi Prognostic significance of p27Kip1, p45Skp2 and Ki67 expression profiles in Merkel cell carcinoma, extracutaneous small cell carcinoma, and cutaneous squamous cell carcinoma
    M T Fernandez-Figueras
    Department of Pathology, Hospital Universitari Germans Trias i Pujol, Catalonia, Spain
    Histopathology 46:614-21. 2005
    ....
  64. ncbi Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis
    Rachel E Palmer
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129, USA
    Cancer Cell 2:497-505. 2002
    ..BAIAP3 therefore encodes a transcriptional target of an oncogenic fusion protein that implicates the regulated exocytotic pathway in cancer cell proliferation...
  65. pmc Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma
    Liang Cheng
    Department of Pathology and Laboratory Medicine, Indiana University Medical Center, University Hospital 3465, 550 North University Boulevard, Indianapolis, Indiana 46202, USA
    Am J Pathol 166:1533-9. 2005
    ..Concordant genetic alterations and X chromosome inactivation between small-cell carcinoma and coexisting urothelial carcinoma suggest that both tumor components originate from the same cells in the urothelium...
  66. ncbi Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer
    T Kijima
    Department of Medical Oncology, Dana Farber Cancer Institute, Dana 1234B, 44 Binney Street, Boston, MA 02115, USA
    J Cell Mol Med 7:157-64. 2003
    ..In summary, FN stimulation of SCLC cells leads to enhancement of viability and changes in cytoskeletal function that are partially mediated through the PI3-K pathway...
  67. ncbi Prostate cancer with a normal PSA: small cell carcinoma of the prostate--a rare entity
    Christopher Trotz
    Family Practice Residency Program, Underwood Memorial Hospital, Woodbury, NJ 08096, USA
    J Am Board Fam Pract 16:343-4. 2003
  68. ncbi Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens
    Siobhan A Nicholson
    Department of Pulmonary and Mediastinal Pathology, Armed Forces Institute of Pathology, Washington DC 20306 6000, USA
    Am J Surg Pathol 26:1184-97. 2002
    ..Stage remained the only predictor of prognosis...
  69. ncbi Unusual and underappreciated: small cell carcinoma of the prostate
    Jeffrey S Palmgren
    Division of Urology, Department of Surgery, University of Missouri School of Medicine, Columbia, MO, USA
    Semin Oncol 34:22-9. 2007
    ..Evident from this review is the necessity for further research in the biology of small cell carcinoma progression, in order to improve therapy.
  70. ncbi The pathology of extrapulmonary small cell carcinoma
    Shellaine R Frazier
    Department of Pathology and Anatomical Sciences, University of Missouri School of Medicine, Columbia, MO 65212, USA
    Semin Oncol 34:30-8. 2007
    ..In this article we discuss the pathology of EPSCC with a review of theories of histogenesis, sites of occurrence, diagnostic features, differential diagnosis, molecular alterations, and clinical behavior...
  71. ncbi Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)
    David J Samson
    Technology Evaluation Center, Blue Cross Blue Shield Association, 1310 G St, NW, Washington, DC 20005, USA
    Chest 132:314S-323S. 2007
    ....
  72. ncbi Small-cell carcinoma of the uterine cervix: a clinicopathologic study of 11 cases
    S Tsunoda
    Department of Obstetrics and Gynecology, School of Medicine, Kitasato University, Kanagawa, Japan
    Int J Gynecol Cancer 15:295-300. 2005
    ..Immunohistochemical analysis using several kinds of neuroendocrine markers is helpful in establishing the correct diagnosis in addition to focusing on characteristic histo- and cytopathologic features...
  73. ncbi Extrapulmonary small cell carcinoma (EPSCC): 10 years' multi-disciplinary experience at Charité
    Sebastian Ochsenreither
    Charite, Campus Benjamin Franklin, Department of Medicine III Hematology and Oncology, Hindenburgdamm 30, 12200 Berlin, Germany
    Anticancer Res 29:3411-5. 2009
    Extrapulmonary small cell carcinoma (EPSCC) is a rare disease of highly proliferating neuroendocrine tumor cells. Therapy and outcome of EPSCC patients treated at our institution were retrospectively analyzed.
  74. ncbi Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome
    M G Joseph
    Department of Pathology, University of Western Ontario, London, Ontario, Canada
    Cancer 92:836-42. 2001
    Patients with small cell carcinoma of the lung (SCLC) are known to have an extremely poor prognosis, with a 5-year survivor rate of only 5%. Chemotherapeutic drug resistance is a major obstacle to curative therapy in patients with SCLC.
  75. pmc Regular aspirin use and lung cancer risk
    Kirsten B Moysich
    Roswell Park Cancer Institute, Buffalo, NY, USA
    BMC Cancer 2:31. 2002
    ....
  76. ncbi Small cell carcinoma of the prostate: an underrecognized entity
    S N Nadig
    Department of Urology, Medical University of South Carolina, Charleston, SC 29425, USA
    Can J Urol 8:1207-10. 2001
    ..Historically, there has been little awareness of the rare but lethal small cell carcinoma (SCC) in association with prostate cancer...
  77. ncbi Prognostic factors in extrapulmonary small cell carcinomas. A large retrospective study
    Yu lin Lin
    Department of Internal Medicine, Division of Hematology Oncology, Changhua Christian Hospital, Changhua, Taiwan
    Oncology 72:181-7. 2007
    Extrapulmonary small cell carcinoma (EPSCC) is a heterogeneous group of cancers. The clinicopathological features of EPSCC remain poorly defined.
  78. ncbi [A case of esophageal small cell carcinoma with syndrome of inappropriate antidiuretic hormone secretion]
    Masaki Kanzaki
    Department of Surgery, Doai Kinen Hospital
    Gan To Kagaku Ryoho 37:1941-4. 2010
    A 66-year-old man was referred to our hospital with esophageal tumor. He was diagnosed with esophageal small cell carcinoma by endoscopic biopsy...
  79. ncbi Elevated mortality from lung cancer associated with arsenic exposure for a limited duration
    Hiroto Nakadaira
    Division of Social and Environmental Medicine, Department of Community Preventive Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Japan 951 8510
    J Occup Environ Med 44:291-9. 2002
    ..b>Small cell carcinoma was specific to the exposed patients...
  80. ncbi Hypercalcemic-type of small cell carcinoma of the ovary: characterization of a new tumor line
    H Walt
    Department of Obstetrics and Gynecology, University Hospital, Zurich, Switzerland
    Anticancer Res 21:3253-9. 2001
    The aim of this study was to develop and characterize a mouse xenograft model for the hypercalcemic-type of small cell carcinoma of the ovary (HTSCCO).
  81. ncbi Extrapulmonary small cell carcinoma of the bladder
    Nasir Shahab
    Department of Medicine, University of Missouri Columbia School of Medicine, Columbia, MO, USA
    Semin Oncol 34:15-21. 2007
    ..The majority of cases have been observed in the bladder and prostate. Small cell carcinoma accounts for less than 1% of all bladder tumors...
  82. ncbi Chronic lymphocytic leukaemia, synchronous small cell carcinoma and squamous neoplasia of the urinary bladder in a paraplegic man following long-term phenoxybenzamine therapy
    S Vaidyanathan
    Regional Spinal Injuries Centre, District General Hospital, Southport, Merseyside, UK
    Spinal Cord 44:188-91. 2006
    ..A case report...
  83. pmc Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cells
    D J A de Groot
    Department of Medical Oncology, University Medical Center Groningen, PO Box 30 001, 9700 RB, Groningen, The Netherlands
    Br J Cancer 92:1459-66. 2005
    ..Our findings show that indomethacin increases the cytotoxic activity of doxorubicin in a doxorubicin-resistant SCLC cell line partly via the death receptor apoptosis pathway, independent of Fas...
  84. ncbi p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung
    Maoxin Wu
    Department of Pathology, Mount Sinai School of Medicine, New York, NY, USA
    Am J Clin Pathol 119:696-702. 2003
    ..p63 and TTF-1 appear to be useful for differentiating SCLC from lung PDSCC in formalin-fixed and alcohol-fixed, formalin-postfixed material...
  85. ncbi Primary small cell carcinoma of the nasal cavity with an unusual oral manifestation
    Marco Tarozzi
    Unit of Oral Pathology and Medicine, School of Dentistry, University of Milan, Milan, Italy
    J Oral Pathol Med 36:252-4. 2007
    b>Small cell carcinoma (SCC) is a malignancy that mainly occurs in the lung, with primary lesions in the head and neck being very rare...
  86. doi F-18-FDG-PET/CT imaging of small cell carcinoma of the colon
    Katie Jones
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Nucl Med 33:645-6. 2008
  87. ncbi A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group
    D S Ettinger
    Johns Hopkins Oncology Center, Baltimore, MD 21205
    J Clin Oncol 8:230-40. 1990
    ..Moreover, when the alternating induction chemotherapy was used, long-term maintenance chemotherapy was not needed...
  88. doi Familial small cell carcinoma of the ovary
    Anibal R Martinez-Borges
    Department of Pediatrics, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Pediatr Blood Cancer 53:1334-6. 2009
    ..b>Small cell carcinoma of the ovary is a rare histology and historically has a poor prognosis...
  89. ncbi Primary small cell carcinoma of the cecum
    Dina El Demellawy
    Department of Anatomical Pathology and Laboratory Medicine, McMaster University, Hamilton, Ontario, Canada
    Ann Diagn Pathol 10:162-5. 2006
    Cecal extrapulmonary small cell carcinoma (cESC) is extremely rare, with only single previous report of occurrence in a child. We report a 76-year-old man admitted for evaluation of a cecal mass seen in colonoscopy...
  90. ncbi Extrapulmonary small cell carcinoma: single center experience with 61 patients
    Sung Sook Lee
    Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
    Acta Oncol 46:846-51. 2007
    ..Clinical trials are needed to define adequate treatment strategies for EPSCC...
  91. ncbi Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer
    H Okamoto
    Yokohama Municipal Citizen s Hospital, Yokohama, Kanagawa, Japan
    J Clin Oncol 17:3540-5. 1999
    ..This phase II study was designed to determine the toxicity and efficacy of carboplatin based on Calvert's formula plus the standard dose of intravenous etoposide for elderly patients with SCLC...
  92. ncbi Controlled clinical trial of prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission
    A Laplanche
    Département de Biostatistique et d Epidémiologie, Institut Gustave Roussy, Villejuif, France
    Lung Cancer 21:193-201. 1998
    ..In conclusion, in this study, which had to be closed prematurely, no significant difference was found in terms of the incidence of brain metastases nor in survival...
  93. ncbi Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma
    Anil Potti
    Department of Medicine, University of North Dakota School of Medicine and Health Sciences, 1919 Elm Street North, Fargo, ND 58102, USA
    Lung Cancer 36:257-61. 2002
    ..There exists a need for randomized controlled trials to assess the role of Herceptin (alone or in combination with standard chemotherapy) in patients with ESSCLC...
  94. pmc Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer
    K Matsui
    Second Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Japan
    Br J Cancer 77:1961-5. 1998
    ..1 months for 16 limited-disease (LD) and 8.6 months for 22 extensive-disease (ED) patients. Myelosuppression was the principal side-effect. This regimen is an active regimen in the treatment of elderly SCLC patients...
  95. doi Neuroendocrine small cell carcinoma of the breast: report of a case
    Rin Yamaguchi
    Kurume University Medical Center, Kurume, Japan
    Med Mol Morphol 42:58-61. 2009
    A rare case of neuroendocrine small cell carcinoma (SmCC) of the breast is reported. A 51-year-old postmenopausal woman noticed a nodule approximately 3 cm in diameter in her right upper breast...
  96. ncbi Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group
    N Murray
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
    J Clin Oncol 17:2300-8. 1999
    ..To determine whether an intensive weekly chemotherapy regimen plus thoracic irradiation is superior to standard chemotherapy in the treatment of extensive-stage small-cell lung cancer (ESCLC)...
  97. ncbi Primary esophageal small cell carcinoma with concomitant invasive squamous cell carcinoma or carcinoma in situ
    Junya Yamamoto
    Department of Pathology, Fukuoka University School of Medicine, Japan
    Hum Pathol 34:1108-15. 2003
    Esophageal small cell carcinoma (SmCC) is a rarer, more highly aggressive, and more rapidly growing neoplasm than esophageal squamous cell carcinoma (SqCC)...
  98. ncbi [Expression of CD56, as a potential diagnostic marker, in small cell carcinoma]
    Jing Ping Yun
    State Key Laboratory of Oncology in Southern China, Guangzhou, Guangdong, P R China
    Ai Zheng 24:1140-3. 2005
    b>Small cell carcinoma is a rare malignant disease with high mortality, which is pathologically diagnosed by using routine neuroendocrinal markers, such as neuron-specific enolase (NSE), synaptophysin (SYN), chromogranin A (CgA)...
  99. ncbi Small cell carcinoma of the endometrium: report of three cases and literature review
    A Katahira
    Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai 980 8574, Japan
    Int J Gynecol Cancer 14:1018-23. 2004
    b>Small cell carcinoma of the endometrium is extremely rare. Aim. We reported three cases of this rare tumor and reviewed the literature.
  100. ncbi MRI of small cell carcinoma of the uterine cervix with pathologic correlation
    Dong Hyun Yang
    Department of Radiology, Asan Medical Center, University of Ulsan, College of Medicine, 388 1 Poongnap dong, Songpa Gu, Seoul 138 736, South Korea
    AJR Am J Roentgenol 182:1255-8. 2004
    OBJECTIVE: The purpose of this study was to evaluate the MRI features of small cell carcinoma of the uterine cervix and to correlate those features with pathologic findings...
  101. ncbi Stage I small cell carcinoma of the endometrium: survival and management options
    Aylin Fidan Korcum
    1Department of Radiation Oncology, Akdeniz University School of Medicine, Antalya, 07070, Turkey
    Acta Obstet Gynecol Scand 87:122-6. 2008
    b>Small cell carcinoma (SCC) of the endometrium is a rare but aggressive disease with early systemic involvement. Patient survival is short. To date, no effective treatment protocol has been established...

Research Grants78

  1. Role of IKK in NSCLC: Modulation of SMRT and NF-kappaB
    Marty W Mayo; Fiscal Year: 2012
    ..The overall goal of this project is use these newly identified gene products as novel therapeutic targets for detection and treatment of NSCLC. ..
  2. Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
    Paul J Shami; Fiscal Year: 2012
    ..This new drug then goes one step further: it will improve the quality of life for cancer patients, their caregivers and families by providing a significantly more effective and less painful therapy than is currently available. ..
  3. Biomarkers to Assess Selenium Chemoprevention for NSCLC
    Steven A Belinsky; Fiscal Year: 2012
    ..Studies will also assess whether these same biomarkers can predict cancer recurrence. Finally, a cocktail of agents with minimal side effects is being evaluated that could ultimately be used in the prevention of lung cancer in humans. ..
  4. Stat3 Downstream Genes as Lung Adenocarcinoma Biomarkers
    Cong Yan; Fiscal Year: 2013
    ..This work will identify protein biomarkers for lung cancer diagnosis and prognosis in humans and in animals. ..
  5. Delivery issues in lung cancer CNS metastases
    Edward A Neuwelt; Fiscal Year: 2013
    ..We hypothesize that these approaches will lead to the development of a clinical trial of dynamic MRI and novel therapy that will translate into improved survival of VA patients with lung cancer brain metastases. ..
  6. Endocrine Targets for Prevention of Lung Cancer
    Robert M Bigsby; Fiscal Year: 2012
    ..These minimal studies will pave the way for testing receptor specific estrogen antagonists and additional PR-specific antagonists in prevention of tumor growth and progression in the lung. ..
  7. A Pilot Study of Yoga for Breathing and Quality of Life of Lung Cancer Patients
    JUDITH MARIE FOULADBAKHSH; Fiscal Year: 2013
    ..Measures will be obtained at Baseline, and at three, six, nine and/or twelve-week intervals (depending on the measure), and at three follow- up time points (one, three and six months) post intervention. ..
  8. Targeting Galectin-1 with radiation in lung cancer
    QUYNH THU XUAN LE; Fiscal Year: 2013
    ..These studies will help to establish that Gal-1 is a novel target that can be used in conjunction with RT to improve the treatment outcome in NSCLC. ..
  9. Role of Id1 in NSCLC Progression and Metastasis
    Srikumar P Chellappan; Fiscal Year: 2013
    ..We believe that an in-depth mechanistic analysis as proposed in this application will lead to the development of novel therapeutic agents for non-small cell lungs cancer based on targeting the Id1 protein. ..
  10. Inhibiting EGFR and ER pathways in NSCLC
    Edward B Garon; Fiscal Year: 2013
    ..At the conclusion of this research training, I will be well positioned to function as an independent physician scientist in patient-oriented lung cancer research, and I anticipate competing for independent research funding. ..
  11. Gene Therapy Reduction of Radiotherapy Esophagitis
    Joel S Greenberger; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): A major dose limiting toxicity of chemoradiotherapy of non-small cell carcinoma of the lung is irradiation esophagitis...
  12. Role of POZ-zinc finger proteins in tumorigenesis.
    Pier Paolo Pandolfi; Fiscal Year: 2013
    ..In view of the critical role exerted by this protein in tumorigenesis and embryonic development the further elucidation of POKEMON/LRF function and role in human cancer is of great relevance to biomedical research. ..
  13. Role of Autophagy in Cancer
    Eileen White; Fiscal Year: 2013
    ....
  14. Using Ketogenic Diets to Enhance Radio-Chemo-Therapy Response: A Phase I Trial
    DOUGLAS ROBERT SPITZ; Fiscal Year: 2012
    ....
  15. Polymorphism and mutation spectrum in minorities with non-small cell lung cancer
    David P Carbone; Fiscal Year: 2010
    ..The results should provide tremendous insight into the genomic factors which influence susceptibility, pathogenesis, drug sensitivity, and survival in African-Americans with non-small cell lung cancer. ..
  16. Carboxylesterase-activated Doxazolidine-prodrug for Hepatocellular Carcinoma
    Tad H Koch; Fiscal Year: 2012
    ..Preliminary subcutaneous xenograft experiments indicate tumor growth inhibition in mouse models of liver cancer and non-small cell lung cancer using cancer cells that express CES2. ..
  17. Rigid-rod Peptides as Nanocarriers for Delivery of Cancer Drugs
    Katarzyna Slowinska; Fiscal Year: 2013
    ..This SC-3 support, if awarded, will increase the PI's research output and improve competitiveness for major grant support such as NSF and NIH-RO1 type grants. ..
  18. Metabolic reprogramming: A new paradigm for targeting cisplatin resistant cells
    Medhi Wangpaichitr; Fiscal Year: 2013
    ..Furthermore, the findings obtained from this application can also be used as a platform to investigate possible ways to selectively kill cisplatin resistant cells from other tumor types. ..
  19. Lung Cancer Chemoradiation: Predictors of Survival
    Xifeng Wu; Fiscal Year: 2009
    ..This multivariate prognostic study could have long-term prognostic potential by allowing greater individualization of therapy, based on the genetic makeup of the patient, thereby both increasing efficacy and reducing morbidity. ..
  20. Prognosis and Effectiveness of Advanced Lung Cancer Treatment in the Elderly
    Juan P Wisnivesky; Fiscal Year: 2010
    ..This study will provide information regarding the efficacy of several therapies and may help resolve several controversies regarding the staging and treatment of elderly patients with advanced stage lung cancer. ..
  21. Characterization of lung cancer radiosensitizers from genome-wide RNAi screens
    David Kozono; Fiscal Year: 2013
    ..In so doing, I hope to provide rationale for testing proteasome and/or USP9X inhibition in Phase I/II trials, and to identify biomarkers for patient selection. ..
  22. Protein Kinase C Signaling Mechanisms in Cancer
    Alan P Fields; Fiscal Year: 2013
    ....
  23. Soy isoflavones to augment radiotherapy of lung carcinoma
    Gilda G Hillman; Fiscal Year: 2012
    ..The results of this investigation will have high impact on the management of patients diagnosed with lung cancer. ..
  24. Development of mutant selective EGFR kinase inhibitors against EGFR T790M
    John Chant; Fiscal Year: 2010
    ..Gatekeeper Therapeutics is developing drugs which might be very efficacious and might prolong the survival of a subset of lung cancer patients that are identified by the specific genetic mutations in their cancers. ..
  25. A phase Ib/II study of AZD2171 and radiation for new brain metastases from NSCLC
    APRIL FITZSIMMONS EICHLER; Fiscal Year: 2010
    ..Brain metastases are often fatal, and new therapies are desperately needed. We propose to study AZD2171, an experimental therapy that acts on tumor blood supply, in lung cancer patients with brain metastases. ..
  26. Inflammation in the pathogenesis of lung cancer
    Steven M Dubinett; Fiscal Year: 2013
    ..Each year lung cancer exacts a devastating toll in terms of lives lost and resources expended. It is expected that this VA supported research will ultimately lead to improvement in disease-free survival for veterans with lung cancer. ..
  27. Novel Strategy for Lung Cancer Treatment Using IGF-1R Inhibitor
    Ho Young Lee; Fiscal Year: 2013
    ..abstract_text> ..
  28. Modeling the KIF5B-RET Fusion Gene of Lung Cancer in Vivo
    Jie Wu; Fiscal Year: 2013
    ..This will provide an important resource for the research community to accelerate the generation of mouse models of newly identified molecular lesions. ..
  29. Role of c-Met in SCLC and Potential for Novel Therapy
    Ravi Salgia; Fiscal Year: 2012
    ..In the nucleus, it binds to different proteins such as Pax5 and topoisomerase-I, and the studies proposed will dissect out mechanisms for this. Ultimately, we propose to bring to fruition combination therapies using these molecules. ..
  30. Notch-1 and IGF-1 crosstalk: new therapeutic strategies for NSCLC
    Maurizio Bocchetta; Fiscal Year: 2013
    ..Furthermore, the study will test the clinical usefulness of targeting Notch signaling to treat NSCLC using GSI. Finally, these experiments will elucidate the role of Notch-1 in lung tumorigenicity in vitro and in vivo. ..
  31. Extracellular Sulfatases As Novel Biomarkers For Early Detection of Cancer
    Joanna Phillips; Fiscal Year: 2013
    ....
  32. Inhibition in the progression of preinvasive lung cancer by pomegranate.
    Naghma Khan; Fiscal Year: 2012
    ....
  33. Peroxisome Proliferator-Activated Receptor (gamma) in Lung Cancer
    Raphael A Nemenoff; Fiscal Year: 2013
    ....
  34. Role of Paxillin in Lung Cancer
    Ravi Salgia; Fiscal Year: 2012
    ..Our goal is to study the role of paxillin in lung cancer and ultimately arrive at novel therapy against this difficult disease. ..
  35. UNIVERSITY OF TEXAS SPORE IN LUNG CANCER
    John D Minna; Fiscal Year: 2013
    ..Achievement of the aims and objectives of this proposal will result in a major decrease in the incidence, morbidity and mortality of lung cancer. ..
  36. Role of EGFR in DNA Repair and Radiation Response in Non Small Cell Lung Cancer
    CHAITANYA SURESH NIRODI; Fiscal Year: 2012
    ..The long term goal is to develop a radiotherapeutic strategy that simulates the radiosensitizing effects of TKD-mutated EGFR in NSCLC patients. ..
  37. The role of Vitamin D metabolism in Non-Small Cell Lung Cancer
    Nithya Ramnath; Fiscal Year: 2012
    ..This will have a significant impact on the use of Vitamin D as an adjunct in advanced lung cancer or following resection of early lung cancer to decrease recurrence. ..
  38. Intratumoral genetic therapy for lung cancer
    Steven M Dubinett; Fiscal Year: 2013
    ..abstract_text> ..
  39. Proton-coupled folate/antifolate transport
    ISRAEL DAVID GOLDMAN; Fiscal Year: 2013
    ..Hence, elucidation of the biology of PCFT contributes to the understanding of factors that are determinants of folate homeostasis in man and impact on the pathogenesis of cancer and other folate-deficiency disorders. ..
  40. Innovative Clinical Pathways in Lung Cancer Care for Vulnerable Populations
    Yolonda L Colson; Fiscal Year: 2012
    ....
  41. Nicotine, nicotinic receptors and lung cancer
    Eliot R Spindel; Fiscal Year: 2013
    ....
  42. Assessing the Notch Pathway as a Therapeutic Target in Lung Cancer Adenocarcinoma
    Khaled Hassan; Fiscal Year: 2013
    ..This work presents a novel approach in treating lung cancer by targeting cancer stem cells and provides basis for future clinical trials. ..
  43. Molecular Biomarkers of Small Cell Lung Cancer Behaviour
    Pierre P Massion; Fiscal Year: 2013
    ..Ultimately, by detecting SCLC early in its course, we hope to provide patients and loved ones with decrease pain and suffering and possibly a chance for a cure. ..
  44. HEAT AND RADIATION EFFECTS ON TUMOR MICROCIRCULATION
    Mark Wesley Dewhirst; Fiscal Year: 2013
    ..abstract_text> ..
  45. Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment
    Trever G Bivona; Fiscal Year: 2013
    ..Our overall goal is to define the strategies for CD95-NF-kB inhibition most likely to be maximally effective in appropriately selected lung cancer patients. ! ..
  46. Erythropoietin Blockade for the Treatment of Cancer
    C Anthony Blau; Fiscal Year: 2012
    ..First, we will develop a diagnostic assay to predict which patients are most susceptible to erythropoietin induced tumor growth. Second, we propose a new strategy for treating tumors that is based on erythropoietin blockade. ..
  47. Targeting RET in Lung Cancer
    Pasi A Janne; Fiscal Year: 2013
    ..Findings from these studies have therapeutic implications for patients with cancers harboring genomic alterations in RET and catalyze the development of clinical trials for such patients. ..
  48. Development of GZ38-1, a Novel Protectant of Chemotherapy-Induced Myelosuppressio
    JAY COPELAND STRUM; Fiscal Year: 2013
    ....
  49. Antineuronal antibodies in autoimmune neurological disease
    JOHN EDWARD GREENLEE; Fiscal Year: 2013
    ..Information gained from the research should also be of value in understanding the role of antibody-neuron interactions in host defense against infection and in immunotherapy of degenerative neurological diseases. ..
  50. Targeting the ERCC1/XPF nuclease for cancer therapy
    John J Turchi; Fiscal Year: 2012
    ..Providing a more effective treatment regimen is essential to increase overall survival and enhance quality of life for those diagnosed with cancer. ..
  51. Understanding the role of SKP2 in small cell lung cancer progression
    Brandon Nicolay; Fiscal Year: 2013
    ..This will lead to identification of combined approaches that together with Skp2 knockdown will lead to SCLC cell death. ..
  52. University of Maryland, Baltimore Biomarker Reference Laboratory
    Sanford A Stass; Fiscal Year: 2013
    ..of authority and organizational structure have been established in the UMB BRL to ensure timely performance, efficient communication and rapid translation of findings from the development phase into clinical application ..
  53. EXTENSION OF RADIOTHERAPY RESEARCH
    Raymond E Meyn; Fiscal Year: 2013
    ..When encouraging, results will serve as the basis for formulating compelling regimen for clinical testing. ..
  54. Pharmacogenomics and Mechanisms of Cytidine Analogues
    Liewei Wang; Fiscal Year: 2013
    ....
  55. A Randomized trial of early palliative care for newly diagnosed cancer patients
    JENNIFER SUE TEMEL; Fiscal Year: 2013
    ..We hope that combining palliative care with traditional cancer treatment will not only prove beneficial for patients and their families but also transform comprehensive cancer care. ..
  56. Synthetic cannabinoids as novel therapeutic strategies against non-small cell lun
    Ramesh K Ganju; Fiscal Year: 2012
    ..The proposed research can yield important novel future clinical therapies that will significantly improve lung cancer mortality and promote lung health. ..
  57. A Phase II Study to Test the Correlation of a Radiation Pneumonitis Imaging Bioma
    Thomas M Guerrero; Fiscal Year: 2010
    ..We anticipate the PMRR, the focus of this study, may have a significant impact on the development of drug to reduce radiation treatment toxicity in cancer patients. ..
  58. Defining a Molecularly Distinct Subtype of Non Small Cell Lung Cancer
    Alexander Augustyn; Fiscal Year: 2013
    ....
  59. CD22-targeted Therapeutics for the Treatment of Lung Cancer
    Joseph M Tuscano; Fiscal Year: 2013
    ..This work will study the role of CD22 in NSCLC, the potential for CD22-targeted therapy of NSCLC, and will allow for rapid translation of huHB22.7 to patients with NSCLC. ..
  60. Identification and therapeutic application of miRNA-drivers in lung cancer
    ANDREA LYNN KASINSKI; Fiscal Year: 2013
    ..The identification of miRNAs and targeted-therapies to perturb miRNA imbalance that occurs in cancer is invaluable to the fields of cancer and miRNA biology, and has direct clinical application. ..
  61. Targeted Treatment of Recurrent Small Cell Lung Cancer with Anti-AbnV2 Antibodies
    Roy H L Pang; Fiscal Year: 2011
    ..The proposed research is expected to lead to new successful therapies for managing recurrent SCLC, thereby leading to a higher long- term survival rate for these patients. ..
  62. Inflammation in Oncogenic K-ras-induced Lung Tumorigenesis
    Jonathan M Kurie; Fiscal Year: 2012
    ..We hope to better understand the mechanisms by which tumor/stromal cell interactions promote lung tumorigenesis and to build a rationale to test CXCR2 as a target for lung cancer prevention and therapy. ..
  63. HDAC inhibition for the chemoprevention of lung cancer
    Johann Christoph Brandes; Fiscal Year: 2013
    ..With a 37% absolute risk reduction for lung cancer incidence, this would translate into 55,000 lives saved per year. ..
  64. Integrating cellular and molecular heterogeneity of TKI response in NSCLC cells
    PETER LEE FRICK; Fiscal Year: 2013
    ..This knowledge would help reconcile the promise of targeted therapies with the challenge of tumor heterogeneity, and could have high translational value. ..
  65. Multifunctional PEG Hydrogel Nano/Microparticles for Targeted Treatment of NSCLC
    Patrick J Sinko; Fiscal Year: 2013
    ....
  66. Development of DNA Methylation Markers for Early Detection of Lung Cancer
    Ite A Laird Offringa; Fiscal Year: 2010
    ..The development of sensitive and specific molecular markers for lung cancer is the key to early detection of this disease, and could greatly increase lung cancer patient survival. ..
  67. FDG-PET and V/Q SPECT Acquired During Radiation to Predict Outcomes in Lung Cance
    Feng Ming Kong; Fiscal Year: 2009
    ..If successful, future radiation therapy could be personalized based on their response to radiation and treatment gain could be maximized. ..
  68. VIP AND EGF RECEPTORS IN NON-SMALL CELL LUNG CANCER
    Terry Moody; Fiscal Year: 1991
    ..These studies will further define the cell surface receptors present on lung cancer cells and aid in determining if these receptors can be utilized to develop novel therapeutic approaches for the treatment of lung cancer...
  69. Molecular Characterization of Stage I Lung Cancer
    Ming You; Fiscal Year: 2010
    ..We believe that the 64-gene molecular marker set are validated, adjuvant therapy could be selectively administered to those patients at high risk for relapse. ..
  70. TISSUE AND SERUM INDICATORS OF LUNG CANCER RECURRENCE
    David Harpole; Fiscal Year: 2000
    ..Tissue and serum markers identified by the model can be used to select high risk patients for a prospective, multi-institutional chemotherapy trial for stage I NSCLC. ..
  71. cardiac neoglycosides as cancer drugs
    Charles Hutchinson; Fiscal Year: 2007
    ..In the present study the goal will be to identify drug leads that have the greatest safety index between antitumor activity and potential cardiotoxicity. [unreadable] [unreadable] [unreadable]..
  72. Adenovirus Persistence in Human Lymphoid Tissues
    Linda Gooding; Fiscal Year: 2007
    ..These studies will reveal the potential for persistent adenovirus to contribute to serious chronic diseases such as cancer and autoimmunity. ..
  73. In vivo RNAi nanoparticle cancer gene function reagent
    Martin Woodle; Fiscal Year: 2009
    ..If successful, the resulting reagent is expect to enable rapid advances in understanding this life threatening disease that produce better targeted therapeutic treatment options for patients. ..
  74. A Population-Based Analysis of Mediastinal Staging for Non-Small Cell Lung Cancer
    Farhood Farjah; Fiscal Year: 2007
    ..The body of evidence emerging from this line of work also has implications for quality improvement initiatives and incorporating standardized staging into clinical trials of therapy. [unreadable] [unreadable] [unreadable] [unreadable]..
  75. Biology of CHK2 Kinase In Lung Cancer
    Weixin Wang; Fiscal Year: 2005
    ....
  76. Targeting MRP7 to Overcome Drug Resistance for Ovarian Cancer Therapy by Taxanes
    Zhe Sheng Chen; Fiscal Year: 2010
    ..Finally, the knowledge obtained from this research could assist physicians in improving survival rate of ovarian cancer patients. ..
  77. SPECIFIC INHIBITION OF K-RAS EXPRESSION IN LUNG CANCER
    CHARLES MAYFIELD; Fiscal Year: 1999
    ..These studies will provide critical information on the potential for antigene therapy in humans. ..
  78. Inflammatory Cytokines Associated Symptom Burden in NSCLC Patients Receiving CXRT
    Xin Wang; Fiscal Year: 2009
    ..Finding mechanisms to relieve symptom burden and improve the function of the many patients undergoing curative aggressive cancer treatment such as chemoradiation has immense public health significance. ..